Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + ribavirin versus peginterferon alfa-2a + ribavirin in treatment-naive genotype 2 or 3 chronic hepatitis C
2011-005055-14Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatitis C virus infection comparing Sofosbuvir + ribavirin with Peginterferon alfa-2a + ribavirin (2 arms). Primary endpoint: SVR12. Started Mar 2012; status: completed.
02
Drugs
sofosbuvirribavirininterferon alfa
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-005055-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005055-14.